Clear Search

Showing 1 result for “Vanhoutte F”.

July 2017

Selektif Janus Kinaz 1 İnhibitörü olan Filgotinib'in Romatoid Artrit’de Kısa Vadeli Tedavisi Sonrası Etkinliği, Güvenliği, Farmakokinetiği ve Farmakodinamiği: İki randomize Faz II A Çalışmanın Sonuçları

Arthritis Rheumatol. 2017 Oct;69(10):1949-1959. doi: 10.1002/art.40186

In two 4-week exploratory Phase 2a trials in MTX-inadequate responder (IR) patients with RA, the highly selective JAK1 inhibitor filgotinib met the primary endpoint of ACR20 at Week 4, showing greater response than placebo.Study 1, a proof-of-concept study, included 127 patients randomised to placebo, filgotinib 100 mg BID or filgotinib 200 mg QD. Study 2, was a dose-ranging study and included 91 patients randomised to placebo, filgotinib 30 mg QD, filgotinib 75 mg QD, filgotinib 150 mg QD or fi...

daha fazla…